Eye drug firm Akorn to buy rival Hi-Tech Pharmacal for $640 mln
Aug 27 (Reuters) - Specialty pharmaceutical company Akorn Inc will buy rival Hi-Tech Pharmacal Co Inc for $640 million in cash to expand its eye drug portfolio to other dosage forms such as oral liquids, topical creams and ointments.
Akorn will pay $43.50 per Hi-Tech share, representing a premium of 23.5 percent to Hi-Tech's last close.
The deal will make Akorn the third-largest U.S. generic ophthalmic player and will significantly increase its retail presence in both prescription and over-the-counter products, the companies said in a statement.
- U.S. war veteran released by North Korea returns home |
- Pennsylvania newlyweds "just wanted to murder someone together:" police
- U.S. ice storm causes blackouts, delays in Texas, Arkansas
- WTO overcomes last minute hitch to reach its first global trade deal
- China's parliament: Japan has "no right to criticize" air defense zone